Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,972.50    22.50 (1.15%)
Bid:
1,971.00
Ask:
1,971.50
Spread: 0.50 (0.025%)
Market Cap: £79.05b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

7 Oct 2022 16:38

RNS Number : 2349C
GSK PLC
07 October 2022
 

GSK plc (the 'Company')

Transaction notification

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms S Jackson

b)

Position/status

SVP, Global Communications and CEO Office

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.3049

11

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-10-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D Jackson

b)

Position/status

PCA of Ms S Jackson (SVP, Global Communications and CEO Office)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.3049

11

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-10-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms V Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.3049

31

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-10-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr I Whyte

b)

Position/status

PCA of Ms V Whyte (Company Secretary)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.3049

1,046

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-10-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms D Connor

b)

Position/status

PCA of Mr R Connor (President, Global Vaccines)

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 31 ¼ pence each ('Ordinary Shares')

 

ISIN: GB00BN7SWP63

b)

Nature of the transaction

Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 6 October 2022.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£13.3049

424

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2022-10-06

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHFSWFIWEESEDS
Date   Source Headline
3rd Jan 20257:00 amRNSGSK’s Nucala approved in China for use in CRSwNP
2nd Jan 20253:00 pmRNSTotal Voting Rights
23rd Dec 20243:30 pmRNSDirector/PDMR Shareholding
20th Dec 20249:00 amRNSBlock Listing Application
20th Dec 20247:00 amRNSHeadline results from phase III FIRST trial
16th Dec 20247:11 amRNSJemperli receives US FDA breakthrough designation
16th Dec 20247:05 amRNSEMA grants PRIME Designation for GSK’227
16th Dec 20247:00 amRNSJemperli receives positive CHMP opinion
12th Dec 20243:30 pmRNSDirector/PDMR Shareholding
9th Dec 20246:29 pmRNSOverall survival data presented for Blenrep
9th Dec 20247:05 amRNSBlenrep combination China filing acceptance
9th Dec 20247:00 amRNSNucala COPD submission accepted by US FDA
5th Dec 20247:00 amRNSZhifei China collaboration revised and extended
2nd Dec 20243:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20243:00 pmRNSTotal Voting Rights
27th Nov 20247:00 amRNSGSK liquid meningitis vaccine authorised in EU
25th Nov 20247:00 amRNSBlenrep combinations accepted for US FDA review
22nd Nov 20247:00 amRNSJapan approves first RSV vaccine for adults 50-59
19th Nov 20243:30 pmRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSGLISTEN Trial of Linerixibat Meets Endpoint
14th Nov 20247:00 amRNSGSK announces overall survival results for Blenrep
13th Nov 20243:00 pmRNSBlock listing Interim Review
12th Nov 20243:30 pmRNSDirector/PDMR Shareholding
11th Nov 20243:01 pmRNSGSK publishes provisional 2025 dividend dates
1st Nov 20243:00 pmRNSTotal Voting Rights
30th Oct 20242:29 pmRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNS3rd Quarter Results
24th Oct 20247:00 amRNSNew positive Arexvy data in younger adults at risk
17th Oct 20243:30 pmRNSDirector/PDMR Shareholding
16th Oct 20244:09 pmRNSDirector/PDMR Shareholding
16th Oct 20247:00 amRNSFDA accepts new drug application for gepotidacin
14th Oct 20243:30 pmRNSDirector/PDMR Shareholding
14th Oct 20247:00 amRNSPositive results of ANCHOR trials of depemokimab
11th Oct 20243:33 pmRNSDirector/PDMR Shareholding
10th Oct 20243:30 pmRNSDirector/PDMR Shareholding
9th Oct 20245:48 pmRNSZantac (ranitidine) litigation settlements
8th Oct 202411:45 amRNSPositive efficacy data of Arexvy over 3 seasons
1st Oct 20243:00 pmRNSTotal Voting Rights
24th Sep 20243:30 pmRNSDirector/PDMR Shareholding
24th Sep 20247:00 amRNSPositive EU opinion for GSK liquid Menveo vaccine
18th Sep 20241:20 pmRNSStatement: Zantac (ranitidine) litigation
17th Sep 20247:00 amRNSJapan Filing Acceptance: Blenrep Multiple Myeloma
13th Sep 20247:00 amRNSChina Breakthrough Therapy Designation for Blenrep
12th Sep 20243:30 pmRNSDirector/PDMR Shareholding
12th Sep 20247:00 amRNSPositive mRNA flu vaccine Phase II headline data
11th Sep 20245:27 pmRNSStatement: Zantac (ranitidine) litigation
11th Sep 20243:30 pmRNSChange of Registered Office
11th Sep 20247:00 amRNSUpdate on phase I/II therapeutic HSV vaccine trial
9th Sep 20242:30 pmRNSDepemokimab late-breaking data presented at ERS
6th Sep 20243:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.